Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (Q37835695)

24 August 2017

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (English)

1 reference

24 August 2017

1 reference

R Hajek

8

0 references

Athanasios Dimopoulos

1

object named as

M A Dimopoulos

1 reference

24 August 2017

15

S Zweegman

1 reference

24 August 2017

European Myeloma Network

17

object named as

European Myeloma Network

1 reference

24 August 2017

A Palumbo

2

1 reference

24 August 2017

M Attal

3

1 reference

24 August 2017

M Beksaç

4

1 reference

24 August 2017

F E Davies

5

1 reference

24 August 2017

M Delforge

6

1 reference

24 August 2017

H Einsele

7

1 reference

24 August 2017

J-L Harousseau

9

1 reference

24 August 2017

F Leal da Costa

10

1 reference

24 August 2017

H Ludwig

11

1 reference

24 August 2017

U-H Mellqvist

12

1 reference

24 August 2017

G J Morgan

13

1 reference

24 August 2017

J F San-Miguel

14

1 reference

24 August 2017

P Sonneveld

16

1 reference

24 August 2017

4 February 2011

1 reference

24 August 2017

1 reference

24 August 2017

25

1 reference

24 August 2017

749-760

1 reference

24 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.3

24 August 2017

0 references

cites work

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Treatment of myeloma: cure vs control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Pathogenesis and treatment of renal failure in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Meeting the unmet needs in anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Risky business in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

inferred from DOI database lookup

7 January 2021

based on heuristic

Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2011.3

1 reference

Dimensions Publication ID

24 August 2017

1042228360

0 references

Fatcat ID

release_t4va6ykixzahjlg56bxihc3jem

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/t4va6ykixzahjlg56bxihc3jem

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference